The US biotech company, focusing om messenger RNA therapeutics and vaccines, has announced plans to expand its commercial footprint in Europe across six additional countries.
The announcement reinforces Moderna’s commitment to Europe and vision as a global commercial enterprise, building on the recent announcement of expansion in the Asia-Pacific region, it states in a press release.
Denmark, Norway and Sweden
Moderna plans to establish a commercial presence in Belgium, Denmark, Norway, the Netherlands, Poland, and Sweden to support the delivery of mRNA vaccines and therapeutics locally.
“Europe has played a critical role in Moderna’s ability to manufacture and deliver our COVID-19 vaccine across the world, protecting millions of people from COVID-19 infection, hospitalization, and death. After a decade of pioneering the development of our mRNA platform, I am proud of the growth we continue to achieve,” says Stéphane Bancel, Chief Executive Officer of Moderna. “I look forward to furthering our collaborations with European researchers and partners to leverage our mRNA technology and expand treatment options to improve the lives of patients across Europe.”
In the European Union, the Company’s COVID-19 vaccine and booster are approved for use by the European Commission for active immunization to prevent COVID-19 caused by the SARS-CoV-2 virus in individuals 18 years of age and older. To date, the European Commission has ordered 460 million doses of Moderna’s COVID-19 vaccine, including boosters and the ability to purchase other COVID-19 vaccine candidates from Moderna’s pipeline. Purchase under this agreement is subject to regulatory approval of the booster vaccine candidates by the European Medicines Agency (EMA).